Probiotic Lactobacillus plantarum NCU001563 Alleviates Ulcerative Colitis via Immunomodulation, Microbiota Remodeling, and Production of Armillarivin and Caffeoyl Aspartic Acid
Food Frontiers · 2026-03 · 7 (2)
DOI: 10.1002/fft2.70232 ↗At a glance
Journal article in Food Frontiers, published online on 2026-03-04. Written by Philippe Madjirebaye and 12 co-authors. Cited 1 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China.
Abstract (original language)
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) driven by microbial dysbiosis, barrier dysfunction, and immune dysregulation. Given the limitations of current therapies, we evaluated the probiotic potential of Lactobacillus plantarum NCU001563 (LP) in a mouse model of dextran sulfate sodium (DSS)‐induced UC. LP treatment markedly alleviated disease severity, reducing weight loss, colon shortening, and histological damage. It restored immune balance by decreasing proinflammatory mediators (TNF‐α, IL‐6, IL‐1β, MPO, IgE) and increasing anti‐inflammatory cytokines (IL‐10, TGF‐β2) via modulation of the JAK‐STAT and Smad2 signaling pathways. LP also reversed microbial dysbiosis, reducing pathogenic genera, such as Clostridium_sensu_stricto_1, Escherichia‐Shigella , and Turicibacter , while enriching beneficial genera like Muribaculaceae, Lachnospiraceae_NK4A136_group, Odoribacter, Blautia , and Ruminiclostridium_9 . Metabolomic analysis revealed that LP suppressed proinflammatory pathways (arachidonic acid metabolism) and proinflammatory metabolites (LysoPEs), while upregulating amino acid biosynthesis and enriching anti‐inflammatory metabolites (caffeoyl aspartic acid and armillarivin). Mechanistically, these changes were linked to the inhibition of the JAK‐STAT pathway and the activation of the TGF‐β2/Smad2/IL‐10 axis. These findings demonstrated that LP possesses a protective response via the microbiota–metabolite–immune axis, positioning it as a promising next‐generation probiotic for UC management.
Funding
- Shenzhen Science and Technology Innovation Program
- National Natural Science Foundation of China
Cite
APA
Madjirebaye, P., Ullah, N., Mazhar, M., Mueed, A., Peng, Z., Abaidullah, M., Liao, Y., Fan, Y., Tang, P., Li, J., Xiong, T., Yang, P., & Wu, X. (2026). Probiotic Lactobacillus plantarum NCU001563 Alleviates Ulcerative Colitis via Immunomodulation, Microbiota Remodeling, and Production of Armillarivin and Caffeoyl Aspartic Acid. Food Frontiers, 7(2). https://doi.org/10.1002/fft2.70232
Vancouver
Madjirebaye P, Ullah N, Mazhar M, Mueed A, Peng Z, Abaidullah M, et al. Probiotic Lactobacillus plantarum NCU001563 Alleviates Ulcerative Colitis via Immunomodulation, Microbiota Remodeling, and Production of Armillarivin and Caffeoyl Aspartic Acid. Food Frontiers. 2026;7(2). doi:10.1002/fft2.70232
BibTeX
@article{Madjirebaye2026,
author = {Madjirebaye, Philippe and Ullah, Naeem and Mazhar, Muhammad and Mueed, Abdul and Peng, Zhen and Abaidullah, Muhammad and Liao, Yun and Fan, Yuting and Tang, Ping and Li, Jing and Xiong, Tao and Yang, Pingchang and Wu, Xuli},
title = {Probiotic Lactobacillus plantarum NCU001563 Alleviates Ulcerative Colitis via Immunomodulation, Microbiota Remodeling, and Production of Armillarivin and Caffeoyl Aspartic Acid},
journal = {Food Frontiers},
year = {2026},
volume = {7},
number = {2},
doi = {10.1002/fft2.70232}
}
EUVIMED